5770-40-1

Basic information

• Product Name: 1,3-Dibutyl-pyriMidine-2,4,6-trione
• Synonyms: 1,3-Dibutyl-pyriMidine-2,4,6-trione;1,3-DibutylpyriMidine-2,4,6(1H,3H,5H)-trione;2,4,6(1H,3H,5H)-Pyrimidinetrione, 1,3-dibutyl-
• CAS NO: 5770-40-1
• Molecular Formula: C₁₂H₂₀N₂O₃
• Molecular Weight: 240.2988
• Mol File: 5770-40-1.mol

Chemical Properties

• Melting Point: 49-50 °C
• Boiling Point: 328.3±25.0 °C(Predicted)
• Appearance: /
• Density: 1.096±0.06 g/cm3(Predicted)
• PKA: 6.24±0.40(Predicted)
• CAS DataBase Reference: 1,3-Dibutyl-pyriMidine-2,4,6-trione(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Dibutyl-pyriMidine-2,4,6-trione(5770-40-1)
• EPA Substance Registry System: 1,3-Dibutyl-pyriMidine-2,4,6-trione(5770-40-1)

Safety Data

• Hazardous Substances Data: 5770-40-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1,3-Dibutyl-pyrimidine-2,4,6-trione is used as a building block in the synthesis of various drugs and active pharmaceutical ingredients. Its unique structure and properties make it a valuable component in the development of new medications.
Used in Agrochemicals:
1,3-Dibutyl-pyrimidine-2,4,6-trione has potential applications in the agrochemical industry, where it can be utilized in the development of new pesticides or other agricultural chemicals.
Used in Food Additives:
1,3-Dibutyl-pyriMidine-2,4,6-trione also has potential uses in the food additives industry, where it may be employed to enhance the properties of certain food products or to improve their shelf life.
It is important to handle 1,3-Dibutyl-pyrimidine-2,4,6-trione with care due to its potential health hazards and environmental impact. Proper safety measures should be taken during its production, use, and disposal to minimize any adverse effects.

Upstream product

• 1792-17-2 N,N'-di-n-butylurea 
• 141-82-2 malonic acid 
• 111-36-4 n-butyl isocyanide 
• 1663-67-8 malonoyl dichloride 
• 619-37-4 N,N-di-n-butylurea 
• 161494-64-0 1,3-dibutylpyrimidine-2,4,5,6-tetraone 5-oxime 

Downstream Products

• 99108-12-0 5-Aminomethylen-1,3-dibutylbarbitursaeure 
• 1000063-42-2 5-[4-(di(2-(cholesteryloxycarbonyl)ethyl)amino)benzylidene]-1,3-dibutylpyrimidine-2,4,6-trione 
• 1089734-16-6 5-{1-{3,5-bis[(6-(3,3-dimethyl)butyrylamino)pyridin-2-yl]carbamoyl}phenyl-2,6-dimethylpyridin-4-ylidene}-1,3-dibutylpyrimidine-2,4,6-trione 
• 1313712-22-9 1,3-dibutyl-5-(1,3-dithian-2-ylidene)pyrimidine-2,4,6(1H,3H,5H)-trione 

Relevant articles and documents

Pyrazolopyrimidine-2,4-dione sulfonamides: Novel and selective calcitonin inducers

A series of pyrazolo[4,3-d]pyrimidine sulfonamides and pyrazolo[3,4-d]pyrimidine sulfonamides have been synthesized. These compounds increase transcription of a calcitonin - luciferase promoter and production of cellular calcitonin in a calcitonin - secre

Non-Fullerene Small Molecule Acceptors Containing Barbituric Acid End Groups for Use in High-performance OPVs

We synthesized two new bithiophene-based small molecules, TT-BBAR, and TT-OBAR, having butyl- and octyl-substituted barbituric acid (BAR) groups, respectively, via a well-known synthetic method, the Knoevenagel condensation, in high yield. These small mol

Malonic Acid Derivatives on Duty as Electron-Withdrawing Units in Push–Pull Molecules

Based on the 2-(N-piperidinyl)thiophene central donor, 32 model push–pull molecules with systematically varied malonic acid-derived peripheral acceptors have been prepared. Further property tuning has been achieved by modifying the π-linker and the structural arrangement (linear vs. quadrupolar D–π–A systems). Malonic acid derivatives such as cyanoacetic acid, malondinitrile, diethyl malonate, Meldrum′s acid, and N,N′-dibutyl(thio)barbituric acid as well as 1,3-diketo analogues dimedone and indan-1,3-dione were employed as acceptor moieties. Knoevenagel condensation with four thiophene aldehydes afforded the target chromophores in satisfactory yields. The electron-withdrawing abilities of malonic acid acceptors were examined both by experiment including X-ray analysis, differential scanning calorimetry, electrochemistry, and UV/Vis absorption spectroscopy, and by DFT calculations. Details of the structure–property relationships have been elucidated. According to the increasing electron-withdrawing ability, the widely used malonic acid acceptor units can be ordered: diethyl malonate ≤ cyanoacetic acid malondinitrile Meldrum's acid dimedone ≤ N,N′-dibutylbarbituric acid indan-1,3-dione ≤ N,N′-dibutylthiobarbituric acid.

N,N′-Dibutylbarbituric acid as an acceptor moiety in push-pull chromophores

Twelve novel D-π-A chromophores with the N,N′-dibutylbarbituric acid acceptor, the N,N-dimethylamino donor and a systematically extended π-linker were synthesized. The extent of intramolecular charge-transfer, structure-property relationships and nonlinear optical properties were further investigated by X-ray analysis, electrochemistry, UV/Vis absorption spectra, calculations and EFISH experiments.

PROLYL HYDROXYLASE INHIBITORS

The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I), (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

PTH AGONISTS

This invention relates to uracil-derived compounds of forumlas(I) and (II) which are agonists of the parathyroid hormone type I receptor (PTH1R) and as such are useful for the treament of osteoporosis.

Photoprotection compositions comprising certain chelating agents

The subject invention relates to methods and compositions comprising: a) from about 0.1% to about 5% of a compound having the structure selected from the group consisting of: STR1 wherein each R is independently selected from the group consisting of hydrogen, alkyl, and aryl; each R' is independently selected from the group consisting of hydrogen, alkoxy, and alkyl; Z and Z' are independently selected from the group consisting of NH, O, and CH2 such that when Z or Z' is NH, the other is not O; or a pharmaceutically acceptable salt of any of the aforementioned compounds; and b) a pharmaceutically-acceptable topical carrier.